← Russell 3000 cross-section

KRRO Korro Bio, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$197m
Revenue TTM
$2m
Net income TTM
$-107m
Free cash flow
$-68m
Composite score
Sector rank
#2879

Valuation

P / E
EV / EBITDA
EV / sales
34.4
FCF yield
-34.65%
Earnings yield vs 10-yr
-58.83pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,477.1%
EBITDA margin
-4,515.1%
ROE
-103.3%
ROIC
Revenue growth

Insider activity, last 90 days

Net open-market
$-4.83m
Buyers
1
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Delays or difficulties in patient enrollment or difficulties retaining trial participants, including as a result of the availability of existing or other investigational treatments, can result in increased costs, longer development times or termination of a clinical trial. In connection with the growth and advancement of our pipeline, we expect that we will need to increase the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, and as any development candidates near later stage clinical trials and potential commercialization by us, and sales and marketing. …Korro Bio, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →